Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
RESEARCH TOOLSreports
Top Page
NeuroOne Medical Technologies
(NASDAQ:NMTC)
46Neutral
NeuroOne Medical Technologies (NMTC) vs. S&P 500 (SPY)
Market Cap
$25.37M
Dividend YieldN/A
Average Volume (3M)326.41K
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue Growth210.76%
EPS Growth61.22%
CountryUS
Employees17
SectorHealthcare
Sector Strength65
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.27
Shares Outstanding47,385,525
10 Day Avg. Volume472,519
30 Day Avg. Volume326,411
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.53
Price to Cash Flow (P/CF)38.20
P/FCF Ratio38.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NeuroOne Medical Technologies Business Overview & Revenue Model
Company DescriptionNeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
How the Company Makes MoneyNeuroOne Medical Technologies generates revenue primarily through the sale of its medical devices and technologies to hospitals, clinics, and healthcare providers. Key revenue streams include sales of its thin-film electrode systems, which are used in various neurological procedures. The company also potentially earns income from partnerships, collaborations, and licensing agreements with other firms in the medical technology sector. These partnerships can provide additional funding, resources, and distribution channels, contributing to NeuroOne's earnings. Furthermore, the company might receive grants or research funding aimed at advancing its technology and expanding its product offerings.
NeuroOne Medical Technologies Financial Statement Overview
Summary
NeuroOne Medical Technologies demonstrates robust revenue growth but continues to face significant profitability and cash flow challenges. Despite improving stockholders' equity, the company operates with ongoing losses and increased liabilities, highlighting the need for enhanced operational efficiency and cash flow management.Income Statement
NeuroOne Medical Technologies shows improving revenue with a significant increase from $3453003 in the previous annual period to $5749521 in TTM, reflecting strong revenue growth. However, the company consistently operates at a loss with negative net income and negative EBIT and EBITDA margins, indicating ongoing operational challenges.30
Negative
Balance Sheet
The company's balance sheet indicates moderate leverage with a debt-to-equity ratio of 0.08. Stockholders' equity has improved from previous periods, reflecting a stronger equity position. However, total liabilities have increased, which could pose future financial risks.45
Neutral
Cash Flow
The cash flow position remains challenging, with negative operating cash flow and free cash flow indicating cash burn. However, the improvement in free cash flow from the previous annual period suggests efforts towards better cash management. The company's reliance on financing activities remains high.35
Negative
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.75M | 3.45M | 1.95M | 171.17K | 178.15K | 1.93M | Gross Profit |
| 2.74M | 1.08M | 456.52K | -70.79K | -97.75K | 63.12K | EBIT |
| -6.79M | -11.89M | -11.96M | -10.03M | -10.22M | -4.90M | EBITDA |
| -6.34M | -11.84M | -11.76M | -9.91M | -9.80M | -4.85M | Net Income Common Stockholders |
| -7.19M | -12.32M | -11.86M | -10.00M | -9.95M | -13.64M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 9.13K | 1.46M | 5.32M | 11.14M | 6.90M | 4.04M | Total Assets |
| 9.13K | 5.37M | 8.10M | 12.82M | 7.94M | 4.76M | Total Debt |
| 0.00 | 260.16K | 184.40K | 202.90K | 315.67K | 1.32M | Net Debt |
| -9.13K | -1.20M | -5.14M | -7.96M | -6.59M | -2.72M | Total Liabilities |
| 13.45K | 4.55M | 1.85M | 3.22M | 1.38M | 2.69M | Stockholders Equity |
| -4.32K | 822.01K | 6.25M | 9.60M | 6.55M | 2.07M |
| Cash Flow | Free Cash Flow | ||||
| -7.10M | -11.13M | -13.27M | -7.79M | -8.67M | -3.55M | Operating Cash Flow |
| -6.99M | -11.01M | -12.89M | -7.52M | -8.60M | -3.43M | Investing Cash Flow |
| -107.48K | -120.20K | 2.65M | -3.24M | -67.08K | -122.43K | Financing Cash Flow |
| 6.20M | 7.27M | 7.40M | 12.02M | 11.53M | 7.32M |
NeuroOne Medical Technologies Technical Analysis
Negative
0.60
Price Trends
0.89
Negative
0.90
Negative
0.88
Negative
Market Momentum
-0.10
Negative
40.08
Neutral
79.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.89, and below the 200-day MA of 0.88, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 40.08 is Neutral, neither overbought nor oversold. The STOCH value of 79.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.
NeuroOne Medical Technologies Risk Analysis
NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeuroOne Medical Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
46 Neutral | $25.37M | ― | -195.50% | ― | 210.76% | 61.22% | |
40 Underperform | $12.90M | ― | -499.57% | ― | 22.15% | ― | |
35 Underperform | $14.73M | ― | -196.69% | ― | ― | ― | |
30 Underperform | $39.44M | ― | -87.40% | ― | ― | -1455.58% | |
28 Underperform | $31.14M | ― | 1697.39% | ― | 28.57% | -656.56% |
* Healthcare Sector Average
Performance Comparison
NMTC
NeuroOne Medical Technologies
0.60
-0.51
-45.95%
PAVM
PAVmed
0.75
-1.02
-57.63%
RBOT
Vicarious Surgical
6.65
-1.24
-15.72%
IINN
Inspira Technologies Oxy BHN
0.63
-1.25
-66.49%
COCH
Envoy Medical
1.46
-3.60
-71.15%
NXL
Nexalin Technology, Inc.
1.85
0.47
34.06%
NeuroOne Medical Technologies Earnings Call Summary
Earnings Call Date: Feb 12, 2025 | % Change Since: -44.95% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements in revenue growth and product margin improvements, driven by a successful partnership with Zimmer Biomet and strong performance of the OneRF ablation system. Despite an expected revenue decline in the second quarter and limited cash reserves, the overall outlook for fiscal year 2025 remains positive, with confidence in achieving set revenue and margin targets.Highlights
Record-Breaking Revenue and Growth
NeuroOne achieved record product sales of $3.3 million, a 235% increase from $1 million in the first quarter of fiscal 2024. Total revenue for the first quarter was $6.3 million, also a record for the company.
Improved Product Gross Margins
Record product gross margins increased to 58.9% in the first quarter, nearly double from 27% in the first quarter of fiscal 2024.
Partnership with Zimmer Biomet
Expanded partnership with Zimmer Biomet, including exclusive distribution rights for the OneRF ablation system, leading to a $3 million upfront license payment.
Successful OneRF Ablation Procedures
In all but one of the OneRF ablation procedures performed to date, patients are seizure-free, with one patient being seizure-free for over nine months.
Strong Financial Position
Reported net income of $1.8 million compared to a net loss of $3.3 million in the first quarter of fiscal 2024. Operating expenses decreased by 12%.
Regained NASDAQ Compliance
Company regained compliance with NASDAQ's share price listing standards.
Lowlights
Expected Revenue Decline in Q2
Product revenue is expected to decline sequentially in the second quarter of fiscal 2025 due to the completion of initial stocking orders to Zimmer.
Limited Cash Reserves
Cash and cash equivalents were $1.1 million as of December 31, 2024, down from $1.5 million as of September 30, 2024.
Company Guidance
In the first quarter of fiscal year 2025, NeuroOne Medical Technologies Corporation achieved record product sales of $3.3 million, marking a 235% increase compared to $1 million in the same quarter of fiscal 2024. The company reported a total revenue of $6.3 million, including a $3 million license payment from its expanded partnership with Zimmer Biomet. NeuroOne's product gross margins also soared to 58.9%, a significant rise from 27% in the prior year. The company maintained its guidance for fiscal year 2025, projecting product revenue between $8 million and $10 million, reflecting an increase of 132% to 190% over fiscal 2024, and product gross margins between 47% and 51%. With continued product development and strategic partnerships, NeuroOne is poised for substantial growth in fiscal year 2025.NeuroOne Medical Technologies Corporate Events
Business Operations and Strategy
NeuroOne Medical Technologies Shares Strategic Vision with Shareholders
Neutral
Jan 14, 2025
On January 14, 2025, NeuroOne Medical Technologies Corporation shared a Letter to Shareholders from CEO Dave Rosa, detailing the company’s achievements and strategic plans to deliver value. The letter was made available on the company’s website and as part of a current report, emphasizing the forward-looking nature of the statements based on current expectations.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.